Presentations on BET Inhibitor Apabetalone to be made during the American Society of Nephrology Kidney Week, Clinical Trials on Alzheimer’s Disease, and the American Heart Association Scientific Sessions
CALGARY, Alberta, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today its participation during the following leading scientific conferences: American Society of Nephrology (ASN) Kidney Week Reimagined 2020, 13th Clinical Trials on Alzheimer's Disease (CTAD) digital event, and the American Heart Association (AHA) Scientific Sessions virtual experience, featuring OnDemand oral presentations on apabetalone.
Through participation at leading industry events, the Company continues to highlight apabetalone and its ability to regulate multiple biological pathways that underlie chronic disease, as well as presenting new research related to COVID-19. Further details of the presentations are outlined below, and the posters may be found HERE, when available.
ASN Kidney Week, October 22-25, 2020
- Oral Presentation by Dr. Kam Kalantar-Zadeh, MD, MPH, PhD, Professor and Chief, Division of Nephrology, Hypertension, and Kidney Transplantation, University of California Irvine, California, USA: Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with CKD, Diabetes, and Recent Acute Coronary Syndrome: Results from the BETonMACE Trial
º Results of new data analysis in the chronic kidney disease (CKD) pre-specified subpopulation of BETonMACE will be presented, demonstrating reduced cardiovascular risk in those treated with apabetalone - Poster Presentation: Apabetalone, an Inhibitor of BET Proteins, Downregulates Alkaline Phosphatase and Improves Cardiovascular Risk
º Presentation will examine the role of apabetalone in inhibiting alkaline phosphatase in cardiovascular disease (CVD) and CKD, presenting data generated from cell culture models and clinical samples
Note: ePoster Sessions will be made available OnDemand on the ASN Kidney Week Reimagined platform HERE commencing on October 22, 2020 at 10:00 am EDT and will be available through to December 4, 2020.
CTAD, November 4-7, 2020
- Poster Presentation: The epigenetic BET protein inhibitor apabetalone counters brain endothelial activation and monocyte adhesion
º Interactions between endothelial cells and monocytes in the brain contribute to the development and progression of vascular dementia, the presentation will provide insights into the role of apabetalone treatment in regulating these interactions
Note: Poster presentations will be made available to conference registrants on the CTAD 2020 digital platform beginning November 4, 2020.
AHA Scientific Sessions, November 13-17, 2020
- Oral Presentation: BET Protein Inhibitor Apabetalone Suppresses Inflammatory Hyperactivation of Monocytes from Patients with Cardiovascular Disease and Type 2 Diabetes
º Presentation will discuss the important role of macrophage hyperactivation in driving CVD in diabetic patients and demonstrate apabetalone’s reduction of maladaptive gene expression in these cells - Poster Presentation: Apabetalone (RVX-208) Reduces ACE2 Expression in Human Cell Culture Systems, Which Could Attenuate SARS-CoV-2 Viral Entry
º New data will be presented showing apabetalone treatment reduces expression of the angiotensin converting enzyme 2 (ACE2) receptor that is essential for SARS-CoV-2 viral entry, in human cell lines - Poster Presentation: Reduction in the Risk of Major Adverse Cardiovascular Events with Apabetalone, a BET Protein Inhibitor, in Patients with Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the BETonMACE Trial
º A new post-hoc analysis of BETonMACE will be presented examining the risk of major adverse cardiovascular events (MACE) events to enrolled patients according to their concomitant insulin treatment
Note: OnDemand sessions will be available for viewing on the AHA Scientific Session’s virtual platform HERE on November 13, 2020 at 9:00 am CDT and will be available on the virtual platform through to November 17, 2020.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.
BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on:
- Twitter: @Resverlogix_RVX
- LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.